PTGX – Protagonist Therapeutics Inc
Float Short %
9.8
Margin Of Safety %
-24
Put/Call OI Ratio
0.14
EPS Next Q Diff
-0.06
EPS Last/This Y
-6.45
EPS This/Next Y
0.95
Price
57.53
Target Price
69.08
Analyst Recom
1.17
Performance Q
25.2
Relative Volume
0.59
Beta
2.22
Ticker: PTGX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | PTGX | 55.17 | 0.25 | 0.00 | 3157 |
| 2025-07-28 | PTGX | 56.28 | 0.25 | 0.15 | 3157 |
| 2025-07-29 | PTGX | 55.01 | 0.25 | 0.15 | 3157 |
| 2025-07-30 | PTGX | 54.55 | 0.25 | 5.50 | 3169 |
| 2025-07-31 | PTGX | 53.85 | 0.26 | 0.25 | 3208 |
| 2025-08-01 | PTGX | 53.8 | 0.26 | 1.00 | 3216 |
| 2025-08-04 | PTGX | 53.86 | 0.26 | 0.15 | 3217 |
| 2025-08-05 | PTGX | 53.89 | 0.25 | 2.00 | 3490 |
| 2025-08-06 | PTGX | 53.8 | 0.25 | 2.00 | 3490 |
| 2025-08-07 | PTGX | 50.92 | 0.25 | 1.50 | 3498 |
| 2025-08-08 | PTGX | 51.11 | 0.25 | 0.08 | 3513 |
| 2025-08-11 | PTGX | 53.78 | 0.25 | 0.06 | 3513 |
| 2025-08-12 | PTGX | 54.54 | 0.25 | 0.00 | 3511 |
| 2025-08-13 | PTGX | 56.77 | 0.25 | 0.00 | 3511 |
| 2025-08-14 | PTGX | 54.97 | 0.24 | 0.00 | 3613 |
| 2025-08-15 | PTGX | 56.09 | 0.24 | 0.05 | 3621 |
| 2025-08-18 | PTGX | 56.17 | 0.14 | 0.01 | 2981 |
| 2025-08-19 | PTGX | 56.25 | 0.14 | 0.20 | 2999 |
| 2025-08-20 | PTGX | 56.21 | 0.14 | 0.00 | 3001 |
| 2025-08-21 | PTGX | 55.99 | 0.14 | 0.00 | 3002 |
| 2025-08-22 | PTGX | 57.48 | 0.14 | 0.00 | 3004 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | PTGX | 55.15 | -5.0 | - | -1.65 |
| 2025-07-28 | PTGX | 56.20 | -5.0 | - | -1.65 |
| 2025-07-29 | PTGX | 55.01 | -5.0 | - | -1.65 |
| 2025-07-30 | PTGX | 54.62 | -5.0 | - | -1.65 |
| 2025-07-31 | PTGX | 53.86 | -5.0 | - | -1.65 |
| 2025-08-01 | PTGX | 53.83 | -5.0 | - | -1.65 |
| 2025-08-04 | PTGX | 53.83 | -5.0 | - | -1.65 |
| 2025-08-05 | PTGX | 53.90 | -5.0 | - | -1.65 |
| 2025-08-06 | PTGX | 53.89 | -5.0 | - | -1.65 |
| 2025-08-07 | PTGX | 50.96 | -5.0 | - | -1.65 |
| 2025-08-08 | PTGX | 51.07 | -5.0 | - | -1.65 |
| 2025-08-11 | PTGX | 53.79 | -14.3 | - | -1.84 |
| 2025-08-12 | PTGX | 54.52 | -14.1 | - | -1.98 |
| 2025-08-13 | PTGX | 56.72 | -14.1 | - | -1.98 |
| 2025-08-14 | PTGX | 54.99 | -14.1 | - | -1.98 |
| 2025-08-15 | PTGX | 56.08 | -14.1 | - | -1.98 |
| 2025-08-18 | PTGX | 56.19 | -14.1 | - | -1.98 |
| 2025-08-19 | PTGX | 56.25 | -14.1 | - | -1.98 |
| 2025-08-20 | PTGX | 56.24 | -14.1 | - | -1.98 |
| 2025-08-21 | PTGX | 56.04 | -14.1 | - | -1.98 |
| 2025-08-22 | PTGX | 57.53 | -14.1 | - | -1.98 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | PTGX | -3.69 | -0.39 | 10.60 |
| 2025-07-28 | PTGX | -3.69 | -0.42 | 10.59 |
| 2025-07-29 | PTGX | -3.98 | -0.42 | 10.59 |
| 2025-07-30 | PTGX | -3.98 | -0.42 | 10.59 |
| 2025-07-31 | PTGX | -3.98 | -0.42 | 10.59 |
| 2025-08-01 | PTGX | -4.00 | -0.42 | 10.59 |
| 2025-08-04 | PTGX | -4.00 | -0.21 | 10.59 |
| 2025-08-05 | PTGX | -4.00 | -0.21 | 10.59 |
| 2025-08-06 | PTGX | -4.00 | -0.21 | 10.59 |
| 2025-08-07 | PTGX | -4.00 | -0.21 | 10.59 |
| 2025-08-08 | PTGX | -4.00 | -0.21 | 10.59 |
| 2025-08-11 | PTGX | -3.98 | -0.37 | 10.55 |
| 2025-08-12 | PTGX | -3.98 | -0.37 | 9.82 |
| 2025-08-13 | PTGX | -3.98 | -0.37 | 9.82 |
| 2025-08-14 | PTGX | -3.98 | -0.37 | 9.82 |
| 2025-08-15 | PTGX | -3.98 | -0.37 | 9.82 |
| 2025-08-18 | PTGX | -3.98 | 0.23 | 9.80 |
| 2025-08-19 | PTGX | -4.12 | 0.23 | 9.80 |
| 2025-08-20 | PTGX | -4.12 | 0.23 | 9.80 |
| 2025-08-21 | PTGX | -3.98 | 0.23 | 9.80 |
| 2025-08-22 | PTGX | -3.98 | 0.23 | 9.80 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.55
Avg. EPS Est. Current Quarter
-0.62
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-3.98
Institutional Transactions
0.23
Beta
2.22
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
32
Fair Value
44
Quality Score
56
Growth Score
58
Sentiment Score
75
Actual DrawDown %
5.1
Max Drawdown 5-Year %
-85.8
Target Price
69.08
P/E
80.66
Forward P/E
PEG
P/S
17.09
P/B
5.34
P/Free Cash Flow
96.39
EPS
0.71
Average EPS Est. Cur. Y
-1.98
EPS Next Y. (Est.)
-1.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
24.88
Relative Volume
0.59
Return on Equity vs Sector %
-16.9
Return on Equity vs Industry %
-4
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.33
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 130
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading